Added to YB: 2026-02-25
Pitch date: 2025-12-15
ELUT [bullish]
Elutia Inc.
+65.65%
current return
Author Info
No bio for this author
Company Info
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States.
Market Cap
$46.2M
Pitch Price
$0.66
Price Target
2.07 (+85%)
Dividend
N/A
EV/EBITDA
-3.78
P/E
-1.13
EV/Sales
3.25
Sector
Biotechnology
Category
special_situation
Elutia Inc. - $ELUT
ELUT: Biologic co sold EluPro to Boston Scientific for $88M, now has $45-50M net cash vs $32.8M mkt cap. Focusing on NXT-41x for breast recon where complication rates are 15-20% (5-7x higher than pacemakers). CEO w/ proven track record (grew Osiris 41x, sold for $660M). 2027 launch. 50% success odds at 10% mkt share = 3x upside; high success scenario = 10x+ potential.
Read full article (4 min)